Debridement and impacted bone graft mixed with and without bone morphogenetic protein for the treatment of osteonecrosis of the femoral head: a comparative study

Li Zirong,Sun Wei,Shi Zhencai,Wang Bailiang,Zhang Qidong,Guo Wanshou

DOI: https://doi.org/10.3969/j.issn.1674-1439.2012.05.001

2012-01-01

Abstract:Background: It is well-known that the bone morphogenetic protein 2 (BMP2) can accelerate the bone healing, but it is not clear whether or not it would be promote the ability of repairs in osteonecrosis of the femoral head (ONFH) with debridement and impacted bone graft. Objective: The purpose of the study is to compare the clinical outcomes of debridement and impacted bone graft mixed with or without BMP2 for ONFH. Methods: Totally 42 patients (72 hips) with nontraumatic ONFH were followed up. There were 19 males and 23 females. The age of the patients at the time of operation ranged from 22 to 54 years old (an average 30.9). The operations were performed through anterior approach. The window was opened at the junction of the femoral head and neck. Thorough debridement was carried out in the necrotic foci. The artificial bone substitutes were impacted. The rhBMP2 (4mg) were mixed with bone substitutes in addition in the patients of the first group. The necrotic stage was divided into Ⅰto Ⅳ stage according to Association Research Circulation Osseous (ARCO) classification system. The necrotic type was divided into M to L type according to China-Japan Friendship Hospital (CJFH) classification system. The clinical effectiveness was evaluated by Harris hip score (HHS). The imagination was evaluated by pre-and postoperative X-ray films and CT scans. Results: All patients were followed-up from 5 to 7.8 years (an average 6.1 years). The excellent function was obtained in 36 hips, good function in 12 hips and fair function in 7 hips. The survival rate of the femoral head was 76.4 percent. Among them the survival rate was 81.8 percent in the first group and 71.8 percent in the second group (P=0.459). The survival rate was 90.3 percent in ARCO stage Ⅱb, c and only 34.6 percent in ARCO stage Ⅲa (P=0.0285). The survival rate was 95.3 percent in CJFH type C and L1, and only 29.6 percent in CJFH type L3 (P=0.050). Conclusions: The excellent and good function in mid-term can be achieved in the selected patients (ARCO stageⅡb, c and CJFH type C, L1) with impacted bone graft operation. rhBMP2 can promote the operative effectiveness and quality of bone repairing.